Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
| Autor: | Alfonso Gulias-Herrero, Paulina Moreno-Guillén, Alberto Adrián Solís-Ortega, Mónica Chapa-Ibargüengoitia, Oscar Arturo Lozano-Cruz, Israel Vicente Toledo-Coronado, Mariana Cruz-Contreras, Astrid Ruiz-Margáin, Alejandro Campos-Murguía, Carlos Fernando Martínez-Cabrera, Berenice M Román-Calleja, Yulia A. Nevzorova, Francisco Javier Cubero, José A González-Regueiro, Nabila Cruz-Yedra, Deyanira Kúsulas-Delint, Carlos A. Aguilar-Salinas, Ricardo U Macías-Rodríguez |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Blood Platelets
Liver Cirrhosis Male medicine.medical_specialty Liver Pancreas and Biliary Tract Gastroenterology Severity of Illness Index liver steatosis 03 medical and health sciences 0302 clinical medicine Liver Function Tests Fibrosis Risk Factors Internal medicine Severity of illness Medicine Humans Aspartate Aminotransferases Risk factor Mexico Retrospective Studies medicine.diagnostic_test Hepatology business.industry SARS-CoV-2 Fatty liver Acute kidney injury COVID-19 Retrospective cohort study computed tomography Middle Aged medicine.disease Prognosis Respiration Artificial Fatty Liver Liver Research Design 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Female Steatosis business Liver function tests Tomography X-Ray Computed Biomarkers |
| Zdroj: | Digestive and Liver Disease |
| ISSN: | 1878-3562 |
| Popis: | Background Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). Aims To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis. Methods Retrospective cohort study. In hospitalized patients with COVID-19, the presence of liver steatosis was determined by computed tomography scan (CT). Liver fibrosis was assessed using the NAFLD fibrosis score (NFS score), and when altered, the AST to platelet ratio index (APRI) score. Mann-Whitney U, Student´s t-test, logistic regression analysis, Kaplan-Meier curves and Cox regression analysis were used. Results 432 patients were analyzed, finding steatosis in 40.6%. No differences in pulmonary involvement on CT scan, treatment, or number of days between the onset of symptoms and hospital admission were found between patients with and without MAFLD. The presence of liver fibrosis was associated with higher severity scores, higher levels of inflammatory markers, requirement of mechanical ventilation, incidence of acute kidney injury (AKI), and higher mortality than patients without fibrosis. Conclusion The presence of fibrosis rather than the presence of MAFLD is associated with increased risk for mechanical ventilation, development of AKI, and higher mortality in COVID-19 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect